Physician profile
David A Eichenbaum
NPI 1144251356
$1,693,229.26
in general payments reported to CMS, 2019-2025
63 companies · $245K in 2025
The $245K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $329K · 2020: $151K · 2021: $198K · 2022: $272K · 2023: $212K · 2024: $286K · 2025: $245K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $357K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $273K · Travel and Lodging: $48K · Honoraria: $23K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $22K · Food and Beverage: $20K · Education: $20.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $356,624.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $273,486.92 |
| Travel and Lodging | $47,702.17 |
| Honoraria | $23,001.66 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $22,136.50 |
| Food and Beverage | $20,220.91 |
| Education | $20.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $304,970.43 | 2019-2025 | Vabysmo, Susvimo, Lucentis |
| Regeneron Healthcare Solutions, INC. | $215,278.49 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $198,822.67 | 2021-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $164,937.79 | 2019-2023 | |
| Allergan, INC. | $152,050.70 | 2019-2021 | |
| Abbvie INC. | $92,416.33 | 2022-2025 | |
| Genentech, INC. | $84,266.14 | 2019-2025 | Vabysmo, Susvimo |
| Astellas Pharma US INC | $81,222.03 | 2023-2025 | Izervay |
| Ocular Therapeutix, INC. | $77,243.07 | 2019-2025 | Dextenza |
| Eyepoint US, INC. | $71,541.94 | 2019-2024 | |
| F. Hoffmann-La Roche Ag | $45,799.25 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $25,852.89 | 2019-2025 | Eylea, Eylea Hd |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24,198.53 | 2019-2021 | |
| Alimera Sciences, INC. | $23,959.76 | 2019-2024 | Iluvien, Yutiq |
| Dutch Ophthalmic, USA | $23,405.11 | 2019-2024 | Eva, Combined Machine, Tissueblue |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $21,230.73 | 2022-2024 | Xipere |
| US Retina LLC | $21,162.19 | 2019-2021 | |
| Celgene Corporation | $11,470.00 | 2019-2020 | |
| Novartis Pharma Ag | $11,275.00 | 2021 | |
| Roche Products Limited | $8,862.83 | 2021-2022 | |
| Thrombogenics, INC. | $5,295.55 | 2019 | |
| Pfizer INC. | $3,710.00 | 2023 | |
| Hoffmann-La Roche Limited | $3,273.01 | 2021-2022 | |
| Harrow Eye, LLC | $3,004.45 | 2024-2025 | Iheezo, Triesence |
| Ani Pharmaceuticals, INC. | $2,493.59 | 2023-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Alexion Pharmaceuticals, INC. | $2,349.80 | 2023 | |
| Beaver-Visitec International, INC. | $1,635.00 | 2025 | |
| Coherus Oncology, INC. | $1,524.95 | 2022-2024 | |
| Notal Vision, INC. | $1,321.08 | 2019 | |
| Oculus Surgical INC. | $1,194.08 | 2021 | |
| Boehringer Ingelheim International Gmbh | $950.00 | 2024 | |
| W. L. Gore & Associates, INC. | $900.00 | 2025 | Product In Development |
| Alcon Vision LLC | $855.02 | 2021-2025 | Constellation, Unity, Ngenuity |
| Roche Tcrc, INC. | $842.11 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $787.50 | 2023 | Zeposia |
| Mallinckrodt Hospital Products INC. | $666.16 | 2021-2025 | Acthar |
| Sanofi US Services INC. | $441.00 | 2025 | |
| Natus Medical Incorporated | $336.66 | 2023 | |
| Sandoz INC. | $277.71 | 2024-2025 | Cimerli |
| Horizon Therapeutics Plc | $237.64 | 2022-2023 | Tepezza |
| Biogen, INC. | $149.00 | 2022-2023 | |
| Kala Pharmaceuticals, INC. | $124.99 | 2021 | |
| Dompe US, INC. | $122.13 | 2024 | Oxervate |
| Ivantis, INC | $116.62 | 2019 | |
| Spark Therapeutics, INC. | $102.56 | 2019 | |
| Glaukos Corporation | $99.66 | 2024 | Idose |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Neurotech Pharmaceuticals, INC. | $74.92 | 2025 | |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Celltrion USA INC. | $41.38 | 2024 | Vegzelma |
| Samsara Vision | $41.35 | 2025 | Implantable Miniature Telescope (Imt By Dr. Isaac Lipshitz) |
| Astellas Pharma Global Development | $36.49 | 2024 | Izervay |
| Alcon Research LLC | $35.57 | 2022 | |
| Amgen INC. | $19.46 | 2024 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rhythm Pharmaceuticals, INC. | $15.78 | 2022 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,962.87 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$608,141.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Eichenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.